Request Your Free White Paper Now:

"Improving Performance, Safety, and Manufacturing for Today's Therapies"

An exciting look at the next-generation plasmid for manufacturing today’s cell and gene therapies.

Due to growing global demand, there continues to be a significant rise in cell and gene applications. However, efforts to ramp up the production of high-quality and safe plasmid DNA (pDNA) have brought the fundamental challenges of current, outdated industry technologies into focus.

With small backbones and no antibiotic markers, Nanoplasmid™ vectors are proving to be transformative replacements in a wide variety of applications, offering greater safety and efficiency than traditional plasmids. This next-generation vector is being used in 13 clinical trials including eight completed phase I trials, two recruiting or ongoing phase I trials, one ongoing phase II trial, and two completed phase II trials.

Access this timely and insightful whitepaper today to learn more about Nanoplasmid technology, including its specific benefits for various applications.

• Eliminate the possibility of antibiotic resistance gene transfer to patients via an antibiotic free selection system
• Improve manufacturing yield of plasmids used in the production of AAV and lentivirus
• Improved electroporation transfection in vivo and in vitro
• An HDR donor template for CRISPR
• Serving as a Transposons donor template

Offered Free by: Aldevron
See All Resources from: Aldevron